How to Help Your Patients Find Truvada in Stock: A Provider's Guide

Patients calling your office to report they can't find Truvada or generic emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) at their pharmacy is a scenario becoming more common as the PrEP prescribing landscape evolves. This guide provides a practical, actionable workflow to help your team resolve access issues quickly — before a patient misses a dose.

Why Is This Happening? Understanding the Access Landscape

Truvada and generic emtricitabine/TDF are not in an FDA-declared shortage as of 2026. The issue is localized: with brand Truvada's market share declining dramatically (from a blockbuster to ~4,400 brand prescriptions per quarter per IQVIA 2026 data), many retail pharmacies have reduced their standing inventory of brand Truvada. Some may stock only one or two generic manufacturers' versions.

When a patient presents a prescription for Truvada and the pharmacy doesn't stock it, or carries only a version not covered by their insurance plan, the pharmacy may simply report it as "not available." The drug exists — it's a search-and-navigation problem, not a supply crisis.

Step 1: Optimize How You Write the Prescription

The single most impactful upstream change you can make:

Write generically (DAW-0): "Emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg" — allows dispensing of any FDA-approved generic, maximizing fill options

Prescribe 90-day supplies: Reduces refill frequency and minimizes chances of encountering a stockout

Send to preferred specialty pharmacy: Identify one or two specialty HIV pharmacies in your market that reliably stock all formulations and send prescriptions there by default

Step 2: Help Patients Find Stock Using medfinder

When a patient reports a stockout, your front office can use medfinder for Providers. medfinder calls pharmacies near the patient to check which ones can fill the specific medication and dosage, then delivers the results. This saves your staff the time of calling pharmacy after pharmacy and puts actionable information in the patient's hands quickly.

Alternatively, patients can use medfinder directly. Give them the URL: medfinder.com.

Step 3: Navigate Prior Authorization and Formulary Issues

For patients on commercial insurance using Truvada for PrEP:

ACA preventive services mandate: most commercial plans must cover at least one oral PrEP option at zero cost sharing. If the plan covers generic emtricitabine/TDF and the patient received a brand prescription, a generic substitution resolves most PA issues.

If step therapy is required: document that the patient qualifies for the prescribed medication and submit supporting notes. For PrEP, the mandate is clear — plans cannot impose cost sharing on preventive PrEP.

Medicaid: coverage varies by state; some programs prefer generic Truvada over Descovy. If a patient is on Medicaid and encountering formulary issues, contact the state Medicaid program or use a drug assistance bridge.

Step 4: Enroll Patients in Assistance Programs Early

The best time to enroll patients in assistance programs is at initiation, not during a crisis. Key programs for Truvada:

Gilead Advancing Access: Up to $7,200/year in copay assistance for commercially insured patients. No income restrictions. Call 1-800-226-2056 or enroll online at gileadadvancingaccess.com.

Ready, Set, PrEP: Federal program offering free Truvada and Descovy to uninsured patients who have a current HIV-negative test result and a valid PrEP prescription. Enroll at readysetprep.hiv.gov.

State PrEP assistance programs: Many states offer supplemental programs covering lab costs and office visits. Check nastad.org/prep-map for state-specific options.

Step 5: Know When to Bridge or Switch

For HIV treatment patients who cannot find Truvada:

A short supply through a manufacturer sample or Gilead Advancing Access emergency program can bridge while a pharmacy is sourced

If the issue is persistent, consider whether switching the NRTI backbone from TDF to TAF (via Descovy or a TAF-containing complete regimen like Biktarvy) is clinically appropriate based on the patient's resistance profile, renal function, and viral suppression status

For PrEP patients with persistent access issues, consider transitioning to injectable Apretude or Yeztugo if the patient is clinically appropriate and insurance covers it

Practice Management Considerations

Identify your go-to specialty pharmacies now. Don't wait for a patient crisis. Call two or three specialty HIV pharmacies in your area, confirm they stock generic FTC/TDF, and build those relationships.

Train front-office staff. Staff should know to ask patients whether Truvada or generic emtricitabine/TDF is available before the appointment ends — catching the issue early is much easier than managing it after the patient leaves.

Include assistance program information in patient discharge materials. A one-page resource with Gilead Advancing Access and Ready, Set, PrEP contact information prevents scrambling when cost is the access barrier.

For the full clinical briefing on shortage status and monitoring parameters, see: Truvada Shortage: What Providers and Prescribers Need to Know in 2026.